Latest Breaking News On - Inhibrx biosciences inc new - Page 1 : comparemela.com

Why Is Inhibrx Stock Trading Higher Today? - Inhibrx (NASDAQ:INBX), Sanofi (NASDAQ:SNY)

Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected in Q2 2024.